Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

Merrill Keeps 'Strong Buy' on Pfizer


Merrill Lynch says Pfizer 's (PFE) deal to acquire Pharmacia (PHA) for $60 billion shows "very little overlap."

Analyst Steven Tighe says Pharmacia shareholders will receive 1.4 Pfizer share per Pharmacia share. He says Pfizer will be the leading pharmaceutical maker in every major market in the world after the merger. He notes synergies are currently targeted at $2.5 billion by 2005. He thinks greater synergies may be possible. Tighe says the acquisition will be accretive by $0.06 for 2004. Tighe believes the combined entity will see 10% sales growth through 2004. He sees $1.85 2003 earnings per share for the combined entity, and $2.12 for 2004. He maintains his $39 target and rates Pfizer as strong buy.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus